Extension of once-daily oral sofosbuvir plus RBV regimen to 24 weeks for patients with genotype 3 HCV produced high SVR rates comparable to those observed with 12-week regimen in genotype 2, except in treatment-experienced patients with cirrhosis.
Faldaprevir triple therapy associated with 72% to 73% SVR12 rate in treatment-naive patients with genotype 1 HCV after adjusting for trial, race, and genotype 1 subtype.
Interim virologic response rates appeared higher in patients treated for 24 weeks vs 12 weeks and were independent of previous treatment status, the presence of cirrhosis, or other prognostic factors.
In phase IIb trial, triple-therapy regimen for 16 weeks resulted in SVR12 rate of 95% in patients infected with genotype 1b HCV, but only 17% in patients with genotype 1a HCV and IL28B CC genotype.
In a phase III study, SVR24 rates were 87.4% in IFN-intolerant/ineligible patients and 80.5% in previous nonresponders and the regimen was well tolerated with few discontinuations or serious adverse events.
In phase II study, 95% to 100% of treatment-naive patients achieved SVR with 8 weeks comparable to 12 weeks, and 95% to 100% of previous PI failures achieved SVR with 12-week therapy regardless of the presence of cirrhosis.
12-week triple-drug regimens produced 100% SVR in treatment-experienced patients, but 6-week regimen inferior to previous 8-week and 12-week durations in treatment-naive patients.
In a phase II trial, dual-therapy achieved ≥ 90% SVR12 rates in genotype 1b patients regardless of previous treatment experience and was well tolerated with no treatment-related discontinuations.
In pilot study, high SVR12 response rates observed regardless of HCV subtype or inclusion of ribavirin.
Expansion of the AI443-014 phase II trial demonstrated that the all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 produced SVR12 rates in > 90% of patients while being generally well tolerated.
In a small, ongoing phase II study, 81% of patients achieved undetectable HCV RNA by Week 4, and 100% of evaluable patients had SVR4.
In phase IIa study, simeprevir plus sofosbuvir regimens achieved high virologic response rates regardless of treatment duration or inclusion of RBV and were generally well tolerated.
In phase II trial, overall SVR12 rate of 89%, with a toxicity profile consistent with pegIFN/RBV alone, and low rates of discontinuation.
Sofosbuvir/ledipasvir for 12 weeks associated with 100% SVR12 rate, whereas coadministration of a third DAA yielded 90% to 100% SVR4 rates with only 6 weeks of therapy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.